Magnesium in stroke treatment.


Journal Article (Review)

Magnesium is involved in multiple physiological processes that may be relevant to cerebral ischaemia, including antagonism of glutamate release, NMDA receptor blockade, calcium channel antagonism, and maintenance of cerebral blood flow. Systemically administered magnesium at doses that double physiological serum concentration significantly reduces infarct volume in animal models of stroke, with a window of up to six hours after onset and favourable dose-response characteristics when compared with previously tested neuroprotective agents. Small clinical trials have reported benefit, but results are not statistically significant in systematic review. A large ongoing trial (IMAGES) will report in 2003-4 and further trials are planned.

Full Text

Cited Authors

  • Muir, KW

Published Date

  • November 2002

Published In

Volume / Issue

  • 78 / 925

Start / End Page

  • 641 - 645

PubMed ID

  • 12496316

Pubmed Central ID

  • 12496316

Electronic International Standard Serial Number (EISSN)

  • 1469-0756

International Standard Serial Number (ISSN)

  • 0032-5473

Digital Object Identifier (DOI)

  • 10.1136/pmj.78.925.641


  • eng